- Report
- October 2024
- 181 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- August 2024
- 175 Pages
Global
From €4747EUR$5,000USD£4,004GBP
- Report
- May 2024
- 200 Pages
Global
From €3940EUR$4,150USD£3,323GBP
- Report
- July 2024
- 148 Pages
Global
From €2847EUR$2,999USD£2,402GBP
- Report
- October 2020
- 222 Pages
Global
From €2848EUR$3,000USD£2,402GBP
- Report
- March 2018
- 255 Pages
Global
From €2468EUR$2,600USD£2,082GBP
- Report
- November 2022
- 200 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- June 2024
- 92 Pages
Global
From €3500EUR$3,949USD£3,056GBP
- Report
- January 2025
- 132 Pages
Global
From €902EUR$950USD£761GBP
The Dendritic Cell Cancer Vaccine is a type of cancer vaccine that uses a patient's own dendritic cells to stimulate an immune response against cancer cells. Dendritic cells are a type of white blood cell that can recognize and respond to foreign substances in the body. The vaccine works by extracting dendritic cells from the patient's blood, loading them with antigens from the patient's cancer cells, and then reintroducing them into the patient's body. This stimulates the patient's immune system to recognize and attack the cancer cells.
The Dendritic Cell Cancer Vaccine market is a rapidly growing segment of the cancer vaccine market. It is a promising approach to cancer treatment, as it is personalized to the patient and has the potential to be more effective than traditional cancer treatments.
Companies in the Dendritic Cell Cancer Vaccine market include Immunovative Therapies, Inc., ImmunoCellular Therapeutics, Ltd., and OncoImmune, Inc. Show Less Read more
